Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joshua Cohen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 136
- Beta
- -0.20
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 68.53
Financials
Revenue
$0.00-100.0%Net Income
$-43.42MEBITDA
$-43.38MFree Cash Flow
$-31.45MEPS (diluted)
$-0.39Shares Outstanding (diluted)
111.20M+142.0%Operating Expenses
$45.69MCash & Debt
$250.76MDividend per Share
$0.42Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-144.74M | $-1.53 |
| 2024 | $87.37M | $-301.74M | $-4.43 |
| 2023 | $380.79M | $49.27M | $0.73 |
| 2022 | $22.23M | $-198.38M | $-2.98 |
| 2021 | $0.00 | $-87.93M | $-1.52 |
| 2020 | $650.0K | $-42.28M | $-0.79 |
| 2019 | $1.43M | $-14.82M | $-0.26 |
Valuation
AMLXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (11)
- Newsschaeffersresearch.com·4d ago·Neutral
10 Stocks With Massive Short Squeeze Potential Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)yahoo·45d ago·Neutral
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
View source ↗ - Newsfool.com·45d ago·Neutral
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week Analysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.
View source ↗ - Newsbusinesswire.com·47d ago·Negative
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 sha…
View source ↗ - Newszacks.com·47d ago·Neutral
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.
View source ↗ - Newsfool.com·48d ago·Positive
Why Amylyx Pharmaceuticals Stock Skyrocketed Today Amylyx is developing a GLP-1 treatment for people with chronic low blood sugar. The experimental therapy displayed a favorable safety profile in a clinical study.
View source ↗ - Newsseekingalpha.com·48d ago·Positive
Amylyx Pharmaceuticals, Inc. (AMLX) Discusses Positive Phase III LUCIDITY Topline Results for Avexitide in Post-Bariatric Hypoglycemia Transcript Amylyx Pharmaceuticals, Inc. (AMLX) Discusses Positive Phase III LUCIDITY Topline Results for Avexitide in Post-Bariatric Hypoglycemia Transcript
View source ↗ - Newsmarketbeat.com·49d ago·Negative
Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55% Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III LUCIDITY trial of avexitide met its primary endpoint, reducing the composite rate of clinically significant hypoglycemic events by 55% versus placebo in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.
View source ↗ - Newsbenzinga.com·49d ago·Neutral
Amylyx Pharmaceuticals Stock Soars After the Close: Here's Why Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares are trading higher in Monday's after-hours session after the company scheduled a Phase 3 trial results readout for this week.
View source ↗ - Newszacks.com·55d ago·Neutral
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.38 per share
Typical surprise -4.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.39 vs $-0.36miss
- Thu, May 7$-0.37 vs $-0.34miss
- Tue, Mar 3$-0.30 vs $-0.31beat
- Thu, Nov 6$-0.37 vs $-0.43beat
- Thu, Aug 7$-0.46 vs $-0.44miss
- Thu, May 8$-0.42 vs $-0.45beat
Estimates and results for AMLX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AMLX officers and directors.
- Bought
- $189k
- Sold
- $11.2m
3 trades
48 trades
- Bedrosian Camille Lsold
- Bedrosian Camille Lsold
- Frates James Msold
- Frates James Msold
- Mazzariello Ginasold
- Mazzariello Ginasold
- Klee Justin B.sold
- Klee Justin B.sold
49 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Nov 16, 2022 (35d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.